May
12
2022
On demand

Strategic partnering to enable cell therapy commercialization

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

As emerging cell therapies move from towards the commercialization phase, focus has been placed on establishing scalable and reproducible manufacturing processes and incorporating innovations to streamline cell therapy manufacturing. Thermo Fisher Scientific and ArsenalBio come together to discuss how strategic partnering between biotech and pharma can facilitate the challenging transition of moving therapies through the commercialization pipeline.

In this webinar, you will hear about:

  • Innovations in “fit for purpose” closed manufacturing
  • Process optimization through industry partnership and collaboration
  • Bridging the gap between early discovery and late-phase development

Jenessa Smith

Associate Director of Process Development, ArsenalBio

Jenessa trained at the University of Pennsylvania under Daniel J. Powell Jr., studying CAR/TCR T cell product development. Jenessa also started a veterinary clinical trial for CD20-CART treatment of lymphoma in pet dogs in collaboration with Nicola Mason. After finishing her PhD, she spent time in San Diego at Poseida Therapeutics and moved up to San Francisco in 2019. Jenessa's current team is responsible for end-to-end process development for Arsenal Bioscience's CART pipeline

Xavier De Mollerat Du Jeu

Senior Director, R&D, Cell and Gene Therapy Thermo Fisher Scientific

Xavier de Mollerat du Jeu, Ph.D. is the Senior Director of Research and Development in the Cell and Gene Therapy business unit at Thermo Fisher Scientific, developing new products and solutions for cell therapy manufacturing. Prior to this, Xavier was the director of R&D cell and gene therapy in Carlsbad, California, working on developing new closed modular platforms for the clinical manufacture of T cells. Xavier also identified new DNA delivery approaches for hard to transfect cell lines and primary/stem cells and he is the inventor of Lipofectamine® 3000 and the author of several patents around nucleic acid delivery. Additionally, his research focused on new delivery solutions for CRISPR delivery, scalable lentiviral production solutions, mechanical delivery approaches for primary T cells and in vivo delivery of RNAi/mRNA for research and therapeutic application. His team is dedicated to bringing new viral and non-viral delivery solutions for T cells engineering and manufacturing, including automation and closed systems. Xavier studied molecular biology and plant physiology at the University of Montpellier II in France and received his Ph.D. in human genetics in 2003 from Clemson University in South Carolina. His thesis work involved identifying the gene(s) responsible for Split Hand/Split Foot Malformation 3 (SHFM 3). His post-doctoral fellowship research was in the laboratory of Dr. Michael G. Rosenfeld at UCSD, where he studied the roles of microRNAs in pituitary gland development. He joined Invitrogen (Life Technologies, Thermo Fisher Scientific) in 2005.

SPEAKERS

Jenessa Smith
Associate Director of Process Development at ArsenalBio
Xavier de Mollerat du Jeu
Senior Director, R&D, Cell and Gene Therapy at Thermo Fisher Scientific

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
8
Hrs
29
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
8
Hrs
29
Min
Register

Improving T cell therapy manufacturing processes with automation and...

E Zynda, PhD
Evan Zynda, PhD
Evan Zynda, PhD
Staff Scientist, Cell Biology at Thermo Fisher Scientific
26 May 2022
9
Days
8
Hrs
29
Min
Register

Streamlined workflow solutions for cell and gene therapy analytics

A Graband
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
24 May 2022
7
Days
8
Hrs
29
Min
Register

Process development excellence to de-risk and accelerate commercialization...

B Baghbaderani
Behnam Baghbaderani
Behnam Baghbaderani
Global Head, Process Development, Emerging Technologies at Lonza Pharma & Biotech
5 May 2022
Watch now